Icon, a global provider of outsourced development services, has appointed Dr. Susan Anton as director of epidemiology and risk management practice, Icon late phase & outcomes research, and Dr. Pui Leung as senior clinical research physician, Icon Development Solutions.

Anton has over 25 years of experience leading international epidemiologic, health economic, outcomes research and other market access initiatives. She joins Icon from Boehringer Ingelheim Pharmaceuticals, where she was director of U.S. medical outcomes research and registries. In this role, Anton provided strategic approach, design and analytic guidance for comparative effectiveness research, epidemiologic studies and health technology assessment within their medical outcomes research & registries division. Prior to Boehringer Ingelheim, she directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb.

Leung joins Icon with over 23 years of hospital and pharmaceutical industry experience in a variety of medical specialties including diabetes, endocrinology and general medicine. Prior to Icon, he gained 10 years of experience as a senior phase I clinical research physician in two U.K. CROs and has been principal investigator in many trials with a variety of different study designs including first in human studies. Before joining the pharmaceutical industry in 2002, Leung spent 13 years as a hospital physician in the U.K.’s National Health Service (NHS). He is also a member of the Royal College of Physicians U.K., where he is a member of the examination board at the Faculty of Pharmaceutical Medicine.